Clinical trials: Pancreas; Insulinoma
Insulinoma; Pancreas, MEN1
Endoscopic Ultrasound-guided Radiofrequency Ablation for Upper Gastrointestinal Tract Lesions
The goal of this observational study is to evaluate the long-term clinical effectiveness of EUS-RFA and quality of life in patients with pancreatic or adrenal tumors recieving EUS-RFA.
- Conditions
- Insulinoma; Pancreas, MEN1, NETs, Radiofrequency Ablation
- Trial name
- EURAGIL (NCT07272187)
- Testing
- observational study
- Where
- Denmark
- Volunteers
- 138 people
- Sponsor
- Herlev Hospital
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Metastatic Cancer
- Trial name
- NCT00730483
- Testing
- PVA microporous hydrospheres/doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Yale University
Insulinoma
EUS-guided Ethanol Ablation of an Insulinoma
The present study aims to evaluate the feasibility, safety and efficacy of EUS-guided ethanol ablation of an insulinoma.
- Trial name
- EUS (NCT02121366)
- Testing
- EUS-guided ethanol ablation
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Guangxi Medical University
Insulinoma
[68Ga]Ga-HBED-CC-exendin-4 and [68Ga]Ga-NOTA-exendin-4 PET/CT Imaging in the Same Group of Insulinoma Patients
Glucagon-like peptide-1 receptor (GLP-1R)-targeted PET imaging with 68Ga-labeled compounds is able to provide superior sensitivity and specificity to detect insulinoma, like the widely studied [68Ga]Ga-NOTA-exendin-4.
- Trial name
- NCT05034783
- Testing
- [68Ga]Ga-HBED-CC-exendin-4, [68Ga]Ga-NOTA-exendin-4
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking Union Medical College Hospital
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
Thalidomide in Treating Patients With Metastatic Neuroendocrine Tumors
RATIONALE: Thalidomide may stop the growth of neuroendocrine tumors by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating patients who have metastatic neuroendocrine…
- Conditions
- Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Neoplastic Syndrome
- Trial name
- NCT00027638
- Testing
- thalidomide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Insulinoma
The Clinical Application of 68Ga-NOTA-exendin-4 PET/CT in Detecting Insulinoma
The small insulinoma can not be detected by the CT or MRI. We use 68Ga-NOTA-exendin-4 positron emission tomography/computed tomography (PET/CT) to detect the insulinoma for the patient diagnosed with endogenous hyperinsulinemic…
- Trial name
- NCT04979611
- Testing
- 68Ga-NOTA-exendin-4
- Where
- China
- Volunteers
- 60 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Gastrinoma, Glucagonoma
Temozolomide With or Without Capecitabine in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors
This randomized phase II trial studies how well giving temozolomide with or without capecitabine works in treating patients with advanced pancreatic neuroendocrine tumors.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Islet Cell Carcinoma
- Trial name
- NCT01824875
- Testing
- temozolomide, capecitabine
- Where
- 323 sites in United States
- Volunteers
- 144 people
- Sponsor
- ECOG-ACRIN Cancer Research Group
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Cancer
Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer
Phase I trial to study the effectiveness of trastuzumab plus R115777 in treating patients who have advanced or metastatic cancer.
- Trial name
- NCT00005842
- Testing
- trastuzumab, tipifarnib
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Gastrinoma, Glucagonoma
Capecitabine, Temozolomide, and Bevacizumab for Metastatic or Unresectable Pancreatic Neuroendocrine Tumors
The purpose of this research is to evaluate the effectiveness and safety of a combination of capecitabine, temozolomide and bevacizumab in the treatment of advanced pancreatic neuroendocrine tumors.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Pancreatic Polypeptide Tumor
- Trial name
- NCT01525082
- Testing
- Capecitabine, Temozolomide, Bevacizumab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Shaheen Shagufta
Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
This phase II trial studies how well temsirolimus and bevacizumab work in treating patients with advanced endometrial, ovarian, liver, carcinoid, or islet cell cancer.
- Conditions
- Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma, Endometrial Serous Adenocarcinoma, Localized Non-Resectable Adult Liver Carcinoma
- Trial name
- NCT01010126
- Testing
- Bevacizumab, Temsirolimus
- Where
- 61 sites in United States, Canada
- Volunteers
- 252 people
- Sponsor
- National Cancer Institute (NCI)
Insulinoma
Laparoscopy to Remove Pancreatic Tumors (Insulinomas)
This study will determine if laparoscopy can be used successfully to find and remove insulinomas (insulin-secreting tumors of the pancreas).
- Trial name
- NCT00005910
- Testing
- Intraoperative ultrasound
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Gastrinoma, Glucagonoma
Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
Phase II trial to study the effectiveness of romidepsin in treating patients who have locally advanced or metastatic neuroendocrine tumors.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor
- Trial name
- NCT00084461
- Testing
- romidepsin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine Tumors
RATIONALE: Questionnaires that measure quality of life may help doctors identify the effects of treatment and improve the ability to plan treatment for patients with gastrointestinal-related neuroendocrine tumors.
- Conditions
- Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Metastatic Cancer
- Trial name
- NCT00454376
- Testing
- questionnaire administration, quality-of-life assessment
- Where
- 16 sites in Denmark, Germany and 8 more
- Volunteers
- 408 people
- Sponsor
- National Cancer Institute (NCI)
Gastrinoma, Glucagonoma
Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors
This phase II trial studies regorafenib in treating patients with neuroendocrine tumors that have spread from the primary site (place where it started) to other places in the body.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor
- Trial name
- NCT02259725
- Testing
- regorafenib, laboratory biomarker analysis
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- University of Southern California
Hypoglycemia, Insulinoma
Diagnosing and Treating Low Blood Sugar Levels
Hypoglycemia is the term used to refer to lower than normal levels of blood sugar. This study will continue to research the causes of hypoglycemia.
- Trial name
- NCT00001276
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Congenital Hyperinsulinism, Insulinoma
Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma
Low blood sugars are known to cause brain damage in newborn babies. One of the most common causes of low blood sugars persisting beyond the new born period is a condition called congenital hyperinsulinism (HI).
- Trial name
- NCT02021604
- Testing
- Fluorodopa F 18
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Cook Children's Health Care System
Hyperinsulinism
Utility of 18FDOPA PET/MRI for Focal Hyperinsulinism
The purpose of the study is to provide access to 18F-DOPA PET to patients at Washington University and assess the utility of 18F-DOPA PET/MRI as a preoperative tool to detect and localize focal lesions in the pancreas that are…
- Trial name
- 18FDOPA HI (NCT05088798)
- Testing
- 18F-Fluoro Dopa PET/MRI Imaging
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Washington University School of Medicine
Gastrinoma, Glucagonoma
Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine Tumors
This phase II trial is studying how well gefitinib works in treating patients with progressive metastatic neuroendocrine tumors. Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
- Conditions
- Gastrinoma, Glucagonoma, Insulinoma, Metastatic Gastrointestinal Carcinoid Tumor
- Trial name
- NCT00075439
- Testing
- gefitinib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- National Cancer Institute (NCI)
Congenital Hyperinsulinism, Insulinoma
Pasireotide in Hyperinsulinemic Hypoglycemia
This is a small controlled pilot study to assess the effect of subcutaneous pasireotide on preventing hypoglycemia due to hyperinsulinism, including congenital hyperinsulinism and insulinoma.
- Conditions
- Congenital Hyperinsulinism, Insulinoma, Hyperinsulinism
- Trial name
- NCT03053284
- Testing
- Pasireotide 0.6Mg Solution for Injection, Saline Solution
- Sponsor
- Montefiore Medical Center